title: Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
abstract: Studies suggest that the continuous use of bevacizumab, a vascular endothelial growth factor inhibitor, may play a crucial role in improving therapy success in patients with metastatic colorectal cancer. This is a case report of a female 60-year-old patient with colon cancer metastases in the liver and lungs refractory to mFOLFOX6 and FOLFIRI given as first and second-line therapy, respectively, who demonstrated a good response to FOLFOXIRI and bevacizumab as third-line therapy. Bevacizumab may be added to first, second and third-line chemotherapy for palliative treatment of metastatic colorectal cancer, and data indicate an increase in patient survival with a good response rate and low toxicity.
authors.affiliation: Mauro Sérgio Vieira de Melo, Centro de Terapia Oncológica, Rua Dr Sá Earp, 309 Morin, 25625-073 Petrópolis, RJ, Brasil. julio@ctopetropolis.com.br
authors.forename: Julio Vieira
authors.initials: JV
authors.lastname: de Melo
authors.forename: Mauro Sérgio
authors.initials: MS
authors.lastname: Vieira de Melo
authors.forename: Mariana Helena
authors.initials: MH
authors.lastname: Abad
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin